Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase IIb trial compares AR-12286 to latanoprost in ocular hypertension

May 2, 2011

First selective ganglioside biosynthesis inhibitors identified at Zacharon Pharma

May 2, 2011

R-507 and R-545 reduce acute cellular rejection in vivo

May 2, 2011

New bivalent immunotoxin shows promise to treat solid tumors

May 2, 2011

CH-4938056 targets microtubule-associated protein 4 to confer antitumor activity

May 2, 2011

AY-4 inhibits tumor growth in model of head and neck cancer

April 29, 2011

Genetic markers of prostate cancer mortality identified in castration-resistant disease

April 29, 2011

Antibody-drug conjugate BAY-94-9343 is active against mesothelin-expressing tumors

April 29, 2011

Second-generation tumor metabolism inhibitor PENAO shows promise in vitro and in vivo

April 29, 2011

TTAC-0001 displays antitumor efficacy in various models

April 29, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...